Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cancer in migrant populations: evidence from a regional oncology network.

BMC public health·2026

Same author

Lorlatinib and Amivantamab: A Paradigm Shift in <i>EGFR</i> and <i>ALK</i> Positive NSCLC, with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision Making.

Oncology research·2026

Same author

Critique of phase II agents for non-small cell lung cancer: what is our clinical need and which agents have potential?

Expert opinion on investigational drugs·2026

Same author

Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study.

Cancer treatment and research communications·2026

Same author

Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option?

Current oncology (Toronto, Ont.)·2026

Same author

Crizotinib in Patients With <i>ROS1</i>-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS Trial.

JTO clinical and research reports·2025

Search research articles

Related Experiment Video

Updated: Feb 8, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Frontline immunotherapy for NSCLC: alone or not alone?

Cesare Gridelli¹, Francesca Casaluce²

¹Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy. cgridelli@libero.it.

Nature Reviews. Clinical Oncology

|July 12, 2018

Summary

No abstract available in PubMed .

More Related Videos

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

Related Experiment Videos

Last Updated: Feb 8, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014